S R Čačala1,2, H Farrow3,4, S Makhanya3,4, D G Couch5, M Joffe4,6,7, L Stopforth3,8. 1. Department of Surgery, Ngwelezana Hospital, Empangeni, KZN, South Africa. shas.cacala@gmail.com. 2. Department of Surgery, University of KwaZulu-Natal, Durban, KZN, South Africa. shas.cacala@gmail.com. 3. Department of Oncology, Grey's Hospital, Pietermaritzburg, KZN, South Africa. 4. Non Communicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa. 5. Department of Surgery, Ngwelezana Hospital, Empangeni, KZN, South Africa. 6. MRC Developmental Pathways To Health Research Unit, Department of Pediatrics, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa. 7. South Africa Medical Research Council Common Epithelial Cancers Research Centre, University of Witwatersrand, Johannesburg, Gauteng, South Africa. 8. Discipline of Radiotherapy and Oncology, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Abstract
BACKGROUND: Specialist breast cancer nurses (BCNs) have improved the psychological care and follow-up rates of breast cancer (BC) patients. This study sought to determine if breast cancer research workers (BCRWs) as de facto BCNs impacted patients' adherence to treatment by comparing groups with and without these patient navigators; hence assessing our need for BCNs. METHODS: Two groups BC patients booked for primary chemotherapy compared. Study group 1 (SG1): no BCRWs/BCNs. Study group 2 (SG2): BCRWs involvement. Assessment of numbers completing primary chemotherapy, undergoing surgery post-neoadjuvant chemotherapy and BCRWs interventions. RESULTS: SG1: n = 281, 25-89y, mean 52.7y, Stage 4: 35.6%, Stage 3: 64.4%. SG2: n = 154, 21-85y, mean 52.6y, Stage 4: 47.4%, Stage 3: 43.3%, Stage 2: 9%. Primary chemotherapy not completed SG1: 40.2% (113) versus SG2: 13.5% (21); p < 0.00001. SG1: 88% not completing were lost to follow-up. Excluding peri-chemotherapy deaths and discontinuation: SG1: 37.1% did not complete chemotherapy versus SG2: 2.6%, p < 0.00001. SG2: BCRWs: 107 interventions for 58 (37.7%) patients. Therapeutic breast surgery SG1: 103/181 (56.9%) versus SG2: 66/81 (81.5%); p < 0.0001. SG1: main reasons for not having surgery: lost to follow-up during (n = 58) or after (n = 9) chemotherapy. Follow-up SG2: 12-43 months, mortality: 52% (80/154), no lost to follow-ups. SG1: No mortality data. CONCLUSIONS: In our setting, BC patients often do not attend or complete treatments. In this study, BCRWs as de-facto BCNs were beneficial for BC patient care, improving chemotherapy compliance and therapeutic surgical interventions. This highlights the need for BCNs for the management of BC patients in South Africa.
BACKGROUND: Specialist breast cancer nurses (BCNs) have improved the psychological care and follow-up rates of breast cancer (BC) patients. This study sought to determine if breast cancer research workers (BCRWs) as de facto BCNs impacted patients' adherence to treatment by comparing groups with and without these patient navigators; hence assessing our need for BCNs. METHODS: Two groups BC patients booked for primary chemotherapy compared. Study group 1 (SG1): no BCRWs/BCNs. Study group 2 (SG2): BCRWs involvement. Assessment of numbers completing primary chemotherapy, undergoing surgery post-neoadjuvant chemotherapy and BCRWs interventions. RESULTS: SG1: n = 281, 25-89y, mean 52.7y, Stage 4: 35.6%, Stage 3: 64.4%. SG2: n = 154, 21-85y, mean 52.6y, Stage 4: 47.4%, Stage 3: 43.3%, Stage 2: 9%. Primary chemotherapy not completed SG1: 40.2% (113) versus SG2: 13.5% (21); p < 0.00001. SG1: 88% not completing were lost to follow-up. Excluding peri-chemotherapy deaths and discontinuation: SG1: 37.1% did not complete chemotherapy versus SG2: 2.6%, p < 0.00001. SG2: BCRWs: 107 interventions for 58 (37.7%) patients. Therapeutic breast surgery SG1: 103/181 (56.9%) versus SG2: 66/81 (81.5%); p < 0.0001. SG1: main reasons for not having surgery: lost to follow-up during (n = 58) or after (n = 9) chemotherapy. Follow-up SG2: 12-43 months, mortality: 52% (80/154), no lost to follow-ups. SG1: No mortality data. CONCLUSIONS: In our setting, BC patients often do not attend or complete treatments. In this study, BCRWs as de-facto BCNs were beneficial for BC patient care, improving chemotherapy compliance and therapeutic surgical interventions. This highlights the need for BCNs for the management of BC patients in South Africa.
Authors: L J Ritz; M J Nissen; K K Swenson; J B Farrell; P W Sperduto; M L Sladek; R M Lally; L M Schroeder Journal: Oncol Nurs Forum Date: 2000-07 Impact factor: 2.172
Authors: Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer Journal: N Engl J Med Date: 2005-10-27 Impact factor: 91.245
Authors: Kristen J Wells; Tracy A Battaglia; Donald J Dudley; Roland Garcia; Amanda Greene; Elizabeth Calhoun; Jeanne S Mandelblatt; Electra D Paskett; Peter C Raich Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Anna M van Wyk; Desiré L Dalton; Antoinette Kotzé; J Paul Grobler; Prudent S Mokgokong; Anna S Kropff; Bettine Jansen van Vuuren Journal: PLoS One Date: 2019-10-18 Impact factor: 3.240
Authors: Buhle Lubuzo; Khumbulani W Hlongwana; Mbuzeleni Hlongwa; Themba G Ginindza Journal: Int J Environ Res Public Health Date: 2022-06-28 Impact factor: 4.614